title: Lutetium-177 Labeled Peptides: The European Institute of Oncology Experience.
abstract: Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogues has shown encouraging results in various somatostatin receptor positive tumors. Partial remission rates up to 30% have been documented as well as significant improvements in quality of life and survival. This treatment takes advantage of the high specific binding of the radiolabeled peptide to somatostatin receptors overexpressed by the tumors thus being more effective on the tumor cells with less systemic side-effects. The development of macrocyclic chelators conjugated to peptides made possible the stable binding with various radionuclides. In particular 177Lu features favourable physical characteristics with a half-life of 6.7 days, emission of β- with energy of 0.5 MeV for treatment and γ-emissions suitable for imaging. The present contribution describes the learning process achieved at the European Institute of Oncology (IEO) since the first application of 90Y labeled peptides to the therapy of neuroendocrine tumors back in 1997. Continuous improvements led to the preparation of a safe 177Lu labeled peptide for human use. Our learning curve began with the identification of the optimal characteristics of the isotope paying attention to its chemical purity and specific activity along with the optimization of the parameters involved in the radiolabeling procedure. Also the radiation protection issues have been improved along the years and recently more and more attention has been devoted to the pharmaceutical aspects involved in the preparation. The overall issue of the quality has now been completed by drafting an extensive documentation with the goal to deliver a safe and reliable product to our patients.
authors.forename: Angela
authors.initials: A
authors.lastname: Carollo
authors.forename: Stefano
authors.initials: S
authors.lastname: Papi
authors.affiliation: Division of Nuclear Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milano, Italy. marco.chinol@ieo.it.
authors.forename: Marco
authors.initials: M
authors.lastname: Chinol
mesh_terms: D002626:Chemistry, Pharmaceutical / Q000379:methods; D006801:Humans; D008187:Lutetium / Q000008:administration & dosage* / Q000009:adverse effects; D018358:Neuroendocrine Tumors / Q000532:radiotherapy*; D010455:Peptides / Q000008:administration & dosage / Q000009:adverse effects; D011788:Quality of Life; D011868:Radioisotopes / Q000008:administration & dosage / Q000009:adverse effects; D019275:Radiopharmaceuticals / Q000008:administration & dosage* / Q000009:adverse effects; D018000:Receptors, Peptide / Q000378:metabolism; D017481:Receptors, Somatostatin / Q000378:metabolism; D013004:Somatostatin / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives
chemical_list: D010455:Peptides; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D018000:Receptors, Peptide; D017481:Receptors, Somatostatin; D013004:Somatostatin; D008187:Lutetium